Anogen-Yes Biotech

03/18/2026

We’re proud to share that our Mouse Interleukin-1β (IL-1β) ELISA Kit (MEC1010) played a key role in a groundbreaking study published in Nature Communications. This research, led by Shen Liu and team from Shanghai Jiao Tong University, focuses on neuromorphic electro-stimulation using atomically thin semiconductors for damage-free inflammation inhibition.

Read the full article here: https://lnkd.in/epEgahau

Our IL-1β ELISA Kit was used in this study to measure cytokine levels, providing valuable insights into inflammation control at the molecular level. This product is perfect for immunology and inflammation studies and is backed by high accuracy and reliability.

Interested in exploring how our products can enhance your research? Check out our Mouse IL-1β ELISA Kit here and see how we can support your scientific breakthroughs! https://lnkd.in/ewYnsCw4

03/11/2026

A new study from Washington University School of Medicine reports encouraging evidence that anti-amyloid treatment given before symptoms appear may help delay or prevent Alzheimer’s dementia.

Key insights from the research:

🔬 Anti-amyloid therapy significantly reduced amyloid-β plaque accumulation in the brain

🧬 Participants treated before cognitive symptoms showed signs of delayed disease onset

📊 Biomarkers such as amyloid and tau measurements remain critical tools for early detection and monitoring treatment response

These findings reinforce the importance of early diagnosis and targeted therapies in the fight against Alzheimer’s disease.

Read more:
https://medicine.washu.edu/news/anti-amyloid-drug-shows-signs-of-preventing-alzheimers-dementia/

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies

03/04/2026

A recent article in Biomedical Research and Therapy explores the role of amyloid-β plaques and tau neurofibrillary tangles in Alzheimer’s disease and the therapeutic strategies targeting these pathologies.

Key takeaways:

🔬 Alzheimer’s pathology is driven by the accumulation of Aβ plaques and hyperphosphorylated tau proteins, which together accelerate neuronal damage.

💊 Emerging therapies include monoclonal antibodies targeting Aβ and tau, aiming to slow disease progression and promote immune-mediated clearance.

🚀 Advanced delivery technologies such as nanoparticle-based systems and exosome carriers may improve brain targeting and treatment efficacy.

Understanding the interaction between Aβ and tau remains critical for developing next-generation treatments for Alzheimer’s disease.

Read the article:

https://bmrat.org/index.php/BMRAT/article/view/1004

Review Amyloid Beta and Tau Aggregation: The Etiology and Potential Pharmaceutical Approaches for Alzheimer’s Disease Pushpendra Soni 1 Syed Misbahul Hasan 1 Shom Prakash Kushwaha 1, * Kuldeep Singh 1 Arun Kumar 1 Abdul Hafeez 1 Suvaiv 1 Samman 1 Salman Khan 1 Google Scholar PubMed Faculty of Phar...

02/25/2026

New poster data presented at CTAD highlight promising biomarker effects of etalanetug, a tau-targeting immunotherapy. In patients with dominantly inherited Alzheimer’s disease, treatment was associated with reductions in key tau pathology biomarkers in CSF—providing evidence of target engagement and potential disease-modifying activity.

Although further studies are needed to determine clinical impact, these findings reinforce the growing momentum behind tau-directed therapeutic strategies in neurodegenerative disease.

Read the full article: https://www.neurologylive.com/view/ctad-poster-etalanetug-reduces-tau-pathology-biomarkers-dominantly-inherited-ad

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

02/18/2026

A study published in Biology Direct reveals how hypoxia influences microglia and promotes glioma growth through inflammatory cytokine secretion.
Researchers used Anogen’s Multiplex Human Cytokine ELISA Kit (EM10001) to measure cytokines like IL-1β, IL-6, TNF-α, and more, uncovering how IL-1β–NF-κB–heparanase signaling drives tumor progression in glioma.

Anogen is proud to support cancer research with trusted ELISA kits and antibodies.
Learn more: www.anogen.ca

https://www.youtube.com/watch?v=9tCdiFlMWmc

🧠 TREM2 & Inflammation: New Insights into Alzheimer’s DiseaseA recent study highlights the key role of TREM2 in regulating inflammatory responses in macroph...

02/11/2026

A small open-label clinical trial in individuals with dominantly inherited Alzheimer’s disease (DIAD) suggests that tau immunotherapy may significantly reduce tau-related biomarkers in both cerebrospinal fluid (CSF) and plasma.

After treatment, levels of phosphorylated tau and other tangle-associated markers declined noticeably, indicating that the antibody therapy may be engaging its intended target and affecting tau pathology biology. While the study was small and not placebo-controlled, the biomarker reductions provide encouraging biological evidence that anti-tau immunotherapy can alter disease-related processes.

Researchers emphasized that larger, controlled trials are still needed to determine whether these biomarker changes translate into meaningful clinical benefit.

Read the full article: https://www.alzforum.org/news/conference-coverage/after-tau-immunotherapy-tangle-markers-tank-csf-plasma #:~:text=In%20a%20small%2C%20open%2Dlabel%20trial%20in%20people,inherited%20Alzheimer's%20disease%20(DIAD)%2C%20the%20tau%20immunotherapy

After Tau Immunotherapy, Tangle Markers Tank in CSF, Plasma Go to another part Series - Clinical Trials on Alzheimer's Disease (CTAD) 2025: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn Back...

02/05/2026

A major new study has mapped the detailed chemical landscape of the tau protein — a hallmark of over 20 neurodegenerative diseases including Alzheimer’s and CTE — with unprecedented precision. Researchers analyzed brain tissue from 203 patients across multiple tauopathies using a cutting-edge mass spectrometry tool (FLEXITau) that quantifies specific pathological forms of tau.

Instead of broad, “one-size-fits-all” approaches, this tau atlas identifies 145 post-translational modifications and 195 cleavage sites, ranked by disease relevance through machine learning. That gives scientists and drug developers a detailed roadmap of which tau forms to target for diagnostics, imaging, and therapies.

This resource not only informs better precision diagnostics but could also accelerate targeted therapeutic development — and the methodology may be adaptable to other disease-related proteins beyond tau.

Read the full article: https://medicalxpress.com/news/2026-01-molecular-atlas-tau-enables-precision.html

Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current "one-size-fits-all" approach to diagnosing and treating these tauopathies. The study is published in th...

01/28/2026

A Cell Perspective outlines how the field is evolving beyond traditional amyloid-focused treatments to include tau-targeted approaches, neuroinflammation modulation, and multi-modal strategies that better address the complexity of Alzheimer’s disease. These insights highlight a broader therapeutic landscape with potential for future breakthroughs.

Read the full article: https://www.cell.com/cell/fulltext/S0092-8674(25)01368-6

Emerging tau-targeting approaches show promise in slowing Alzheimer’s disease progression, complementing recent advances in FDA-approved anti-Aβ therapies. This perspective outlines the progress in Alzheimer’s disease therapeutic development, highlighting how tau trial outcomes are providing in...

01/22/2026

An early-stage clinical trial has shown that VY7523, an investigational anti-tau agent, demonstrated a positive safety and tolerability profile in patients with early Alzheimer’s disease. As tau pathology is strongly linked to neurodegeneration and cognitive decline, these findings support continued exploration of tau-targeted therapies as a promising avenue beyond amyloid-focused approaches.

🔬 Early safety success is a critical step toward developing disease-modifying treatments for Alzheimer’s.

Read the full article here: https://www.neurologylive.com/view/anti-tau-agent-vy7523-demonstrates-positive-safety-early-alzheimer-trial

Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.

01/14/2026

Anti-amyloid monoclonal antibodies—like lecanemab and donanemab—are changing the landscape of Alzheimer’s disease care by targeting amyloid-β plaques, a core driver of disease. These therapies have shown robust plaque removal and modest slowing of cognitive decline in early AD patients with confirmed amyloid pathology. While challenges remain, this progress marks a pivotal step toward precision neurology and more effective, tailored interventions for Alzheimer’s.

Read the full article here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12470750/

Alzheimer’s disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug Administration (FDA) approvals of anti-amyloid ...

01/07/2026

In 2018 alone, 9.6 million lives were lost to cancer, making it the second leading cause of death globally.

At Anogen, we believe the future of cancer therapy lies in personalization. Immune checkpoint inhibitors—such as PD-1 and PD-L1–targeted therapies, hold tremendous promise, especially when tailored to the unique immune profile of each patient.

By supporting research in PD-1/PD-L1 checkpoint pathways, we aim to empower scientists to advance more precise, effective, and patient-specific cancer treatments.

🔬 Personalized immunotherapy starts with better research tools.

https://www.youtube.com/watch?v=9AIJAGjVkOc

In 2018, 9.6 million people died from cancer, the second largest cause of death worldwide. Finding a cure to cancer has been the focus of medical science for...

12/18/2025

As the year comes to a close, we’d like to thank our customers, partners, and researchers around the world for your trust and collaboration throughout 2025.

We’re proud to support your work in immunology, oncology, neuroscience, and beyond, and we look forward to continuing this journey together in the year ahead.

Wishing you a joyful holiday season and a successful, inspiring New Year!

🎄❄️✨